Open Research will be upgrading the system on Tuesday, 14 July 2026, from 8:15 to 9:00 AM. We apologise for any inconvenience caused.

Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Transport of transforming growth factor-B2 across the blood-brain barrier

Loading...
Thumbnail Image

Date

Authors

McLennan, Ian S
Weible, Michael
Hendry, Ian
Koishi, Kyoko

Journal Title

Journal ISSN

Volume Title

Publisher

Pergamon-Elsevier Ltd

Abstract

The blood-brain barrier acts as an interface between the brain and body through a combination of restrictive mechanisms and transport processes. Substances essential for brain function pass through the barrier either by passive diffusion or by active transport. We report here that [ 125I]-transforming growth factor-β2 (TGF-β2) passes through the blood-brain barrier and blood-nerve barriers, after intravenous, intraperitoneal or intramuscular injections. The entry of the [ 125I]-TGF-β2 to the brain was rapid, saturable and inhibited by co-injection of unlabelled TGF-β2. In contrast, co-injection of unlabelled TGF-β2 increased the retention of [125I]-TGF-β2 in the blood. The [125I]-TGF-β2 transported into the brain was localised by autoradiography to the extracellular space, and was intact as judged by SDS-PAGE. The [125I]-TGF-β2 was widely distributed throughout the brain, with the highest concentrations in the hypothalamus and nerves and the lowest in the cerebral hemispheres. The [125I]-TGF- β2 had a half-life of 4 h in the brain. These results indicate that therapeutically relevant levels of TGF-β2 reach the brain after peripheral administration of TGF-β2.

Description

Citation

Source

Neuropharmacology

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31
abcd